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otulinum neurotoxins (BoNTs) cause botulism by
entering neurons and cleaving proteins that mediate
neurotransmitter release; disruption of exocytosis results
in paralysis and death. The receptors for BoNTs are thought
to be composed of both proteins and gangliosides; however,
protein components that mediate toxin entry have not been
identiﬁed. Using gain-of-function and loss-of-function
approaches, we report here that the secretory vesicle
proteins, synaptotagmins (syts) I and II, mediate the entry of
B
 
BoNT/B (but not BoNT/A or E) into PC12 cells. Further, we
demonstrate that BoNT/B entry into PC12 cells and rat
diaphragm motor nerve terminals was activity dependent
and can be blocked using fragments of syt II that contain
the BoNT/B-binding domain. Finally, we show that syt II
fragments, in conjunction with gangliosides, neutralized
BoNT/B in intact mice. These ﬁndings establish that syts I
and II can function as protein receptors for BoNT/B.
 
Introduction
 
Clostridial neurotoxins (CNT) are the most toxic substances
known. There are eight related toxins; seven botulinum neuro-
toxins (BoNT/A–G) and a tetanus neurotoxin (TeNT;
Simpson, 1981; Schiavo et al., 2000). Each toxin is composed
of a heavy and a light chain; the heavy chain mediates binding
to the surface of specific nerve terminals. Once internalized
via endocytosis, the light chain is translocated from the lumen
of the vesicle into the cytoplasm, where it functions as a
zinc-dependent protease (Schiavo et al., 2000). The light
chain cleaves one or more components of a conserved mem-
brane fusion complex composed of syntaxin, SNAP-25, and
synaptobrevin (syb), thereby blocking exocytosis (Schiavo et
al., 1992, 1993; Blasi et al., 1993a,b). Because of their ability
to selectively disrupt Ca21-triggered exocytosis, the CNTs
have emerged as important tools for the study of membrane
fusion and synaptic transmission (Jahn and Niemann, 1994).
More recently, BoNTs have become useful for the treatment
of muscle dystonias and have emerged as potential biological
weapons (Mahant et al., 2000; Arnon et al., 2001).
The first step in the action of CNTs involves binding to
receptors on the surface of neurons. Current evidence sug-
gests that the receptors are composed of gangliosides and
proteins that cooperate to form high affinity toxin-binding
sites. Alternatively, gangliosides may constitute relatively
low affinity toxin-binding sites that serve to capture CNTs
to facilitate interactions with cell surface receptor proteins
(Montecucco, 1986; Nishiki et al., 1996a). Gangliosides are
ubiquitous glycosphingolipids in the outer leaflet of plasma
membranes. They are classified according to the number
and position of sialic acids present in their head groups.
Polysialiogangliosides, which are present almost exclusively
in neurons and neuroendocrine cells, bind to CNTs with
the greatest avidity (Halpern and Neale, 1995). Although a
protein component is also clearly involved in toxin–cell
recognition, at present, a protein that mediates toxin entry
has not been identified (Schiavo et al., 2000).
Biochemical experiments have led to the identification of a
handful of CNT-binding proteins. In most cases, these binding
proteins do not appear to function as receptors that mediate
entry of the toxins. For example, BoNT/A, B, E, and TeNT
were reported to bind synapsin I and adducin, respectively
(Schengrund et al., 1992, 1993, 1996). Because neither of
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these proteins are exposed to the outside surface of cells,
they are unlikely to function as cell surface receptors.
TeNT was reported to bind Thy-1, a GPI-anchored
plasma membrane protein. However, neurons from mice
lacking Thy-1 are still sensitive to TeNT, suggesting that
Thy-1 is not essential for TeNT entry into cells (Herreros
et al., 2001).
At present, the only remaining candidate receptor pro-
teins for BoNT/B are synaptotagmins (syts) I and II
(Nishiki et al., 1994). These are homologous synaptic ves-
icle membrane proteins thought to function as Ca
 
2
 
 
 
 sen-
sors for exocytosis (Schiavo et al., 1998; Chapman, 2002).
Syts I and II were reported to bind BoNT/B in the pres-
ence of gangliosides; the dissociation constant for the syt
I–BoNT/B complex was 2.3 nM and the dissociation con-
stant for syt II–BoNT/B was 0.23 nM (Nishiki et al.,
1996a). High affinity binding of BoNT/B to fibroblasts
was reconstituted by expression of syt II and incorpora-
tion of exogenous gangliosides into surface membranes.
However, binding did not result in the cleavage of the
BoNT/B target protein, syb II, that had been coexpressed
with syt II, indicating that the toxin was not internalized
(Nishiki et al., 1996b). Although biochemical experi-
ments clearly established that syt binds to BoNT/B, evi-
dence that binding mediates entry into cells is lacking.
Thus, whether this interaction has any functional role re-
mains unknown. More recently, BoNT/A and E have also
been reported to bind syt I, albeit in a ganglioside-inde-
pendent manner (Li and Singh, 1998).
In the current work, we characterized the interactions be-
tween BoNT/B, A, and E with syts I and II, and have inves-
tigated whether syts I and II function as receptors for
BoNT/B. Our data demonstrate that syts I and II mediate
BoNT/B entry into PC12 cells and motor nerve terminals.
Moreover, the action of BoNT/B on these model systems in
vitro and in mice in vivo can be neutralized by syt II frag-
ments that contain the toxin-binding domain.
 
Results
 
A region within the luminal domain of syts I and II 
mediates direct interactions with BoNT/B
 
To assay for direct syt–BoNT interactions, fragments of syts
I and II were immobilized as GST fusion proteins and used
as an affinity matrix to pull down BoNT/A, B, or E in the
presence and absence of gangliosides. For these experiments,
we included two other syt isoforms, IV and IX, as well as
full-length syb II, as negative controls. The structures of the
syt fragments are shown in Fig. 1 A (top). Because each frag-
ment contains a transmembrane domain, binding assays in-
cluded 0.5% Triton X-100; thus, gangliosides were pre-
sented as mixed micelles. In contrast to a previous paper (Li
and Singh, 1998), we did not observe detectable binding of
BoNT/A or E to any of the immobilized proteins (Fig.
1 A, middle), even when relatively high concentrations of
BoNT/A and E were used (300 nM; unpublished data), in-
dicating that these toxins do not bind to the syt fragments
used in our assays.
Under identical conditions, we observed that BoNT/B
binds syts I and II. Although syt I–BoNT/B interactions
were strictly dependent on gangliosides, syt II bound
BoNT/B in the absence of gangliosides (Fig. 1 A, middle).
Reducing the concentration of bead-immobilized GST–syt
II fusion protein revealed that gangliosides can enhance syt
II–BoNT/B interactions (Fig. 1 A, bottom), but this interac-
tion is clearly less dependent on gangliosides. These findings
are consistent with previous data showing that syt II binds
BoNT/B more tightly than does syt I (Nishiki et al., 1996a);
presumably, the higher affinity syt II–BoNT/B interaction is
less reliant on gangliosides. Syt I/II–BoNT/B interactions
are specific because binding to an analogous region of syt IV
or syt IX, or to full-length syb II, was not detected (Fig. 1 A,
middle).
If syts I and II are physiologically relevant receptors for
BoNT/B, binding must be mediated by the region of syt
Figure 1. Screening for interactions 
between syt isoforms and BoNT/A, B, 
and E. (A) Top; schematic diagram of the 
syt constructs used in the GST pull-down 
experiments. To facilitate purification, 
all syt constructs lacked a C2B domain; 
the arrow indicates the COOH terminus 
of the truncated syt. The transmembrane 
domain is indicated by a black rectangle. 
Middle; GST or the indicated GST fusion 
proteins were incubated with 30 nM 
BoNT/B, A, and E, either with ( ; 25 
 g/ml) or without ( ) gangliosides in 
100  l TBS. 17% of the bound materials 
were analyzed by SDS-PAGE and 
immunoblotting using anti-CNT pAbs. 
“Total” corresponds to 80 ng toxin. 
In the bottom panel, the amount of 
fusion protein was varied as indicated. 
(B) Binding assays were performed as in A. 
NH2-terminal fragments of syts II and IX 
served as positive and negative controls, respectively, and two chimeric constructs, in which the luminal domains of syts II and IX were 
swapped, were tested for toxin-binding activity. (C) Binding assays were performed as in A using immobilized syt II 1–87 and the indicated 
concentrations of BoNT/B. Bound toxin was visualized by staining with Coomassie blue; binding was stoichiometric at saturation. The heavy 
chain (H) of BoNT/B runs at 100 kD, the light chain (L) runs at 50 kD. The asterisk denotes a proteolytic fragment of GST-syt II 1–87.T
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that is exposed outside of cells (i.e., the luminal domain)
during cycles of exocytosis and endocytosis. To clarify how
BoNT/B binds to syt II, we first used syt II and syt IX chi-
meras. Swapping the luminal domains of these proteins was
sufficient to transfer the BoNT/B-binding activity from syt
II to syt IX (Fig. 1 B), indicating that BoNT/B binding is
mediated by the luminal domain of syt II. Consistent with
this finding, a shorter fragment of syt II, composed of only
the luminal and transmembrane domain (residues 1–87),
mediated stoichiometric binding of the toxin (Fig. 1 C).
Truncation analysis was used to further map the toxin-
binding site of syts I and II. Within the luminal domain of
syt II, residues 40–60, which are adjacent to the transmem-
brane domain, are critical for toxin binding (Fig. 2 A). We
note that fragment 61–267 of syt II can bind gangliosides
via its transmembrane domain (residues 61–87; Kozaki et
al., 1998), yet this fragment fails to bind BoNT/B in the
presence of gangliosides (Fig. 2 A, middle). These data sug-
gest that gangliosides do not directly mediate toxin binding
under our assay conditions, but rather cooperate with the lu-
minal domain to form high affinity BoNT/B-binding
sites.  The analogous membrane proximal region of syt I
(residues 32–52) was also critical for binding of BoNT/B
(Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200305098/DC1). This segment is highly conserved be-
tween syts I and II (Fig. 2 B); minor sequence differences
may account for the differences in affinity for BoNT/B
(Nishiki et al., 1996a). We note that the isolated luminal
domain of syt II (residues 1–61) but not syt I (residues 1–53),
bound to BoNT/B (Fig. 2 A and Fig. S1). This result is
likely due to the strong ganglioside requirements for syt
I–BoNT/B interactions; deletion of the transmembrane do-
main of syt I abolishes ganglioside binding (Kozaki et al.,
1998), and thereby decreases BoNT/B-binding activity.
The mapping experiments we have just described suggest
that residues 40–60 of syt II comprise the BoNT/B-binding
domain. To test this directly, a synthetic peptide (P21) cor-
responding to this segment of syt II was immobilized on
beads and used as an affinity matrix. This peptide binds di-
rectly to BoNT/B, although less avidly than do longer frag-
ments of syt II because detectable binding required higher
concentrations of the toxin (Fig. 2 C, top). A scrambled ver-
sion of this peptide, P21S, served as the negative control.
Furthermore, P21, but not P21S, was able to competitively
inhibit syt II–BoNT/B interactions (Fig. 2 C, bottom). P21
also inhibited syt I–BoNT/B interactions (unpublished data).
Together, these experiments establish that residues 40–60 of
syt II largely mediate binding of BoNT/B.
 
Syt I mediates ganglioside-dependent binding 
and entry of BoNT/B into PC12 cells
 
The experiments described above demonstrate that syts I
and II bind to BoNT/B through a conserved region in their
ectodomains. However, the key question is whether syt I or
syt II mediate entry of the toxin; namely, are they functional
protein receptors for BoNT/B? To address this question, we
first used PC12 cells, a neuroendocrine cell line that serves as
a model system to study Ca
 
2
 
 
 
-triggered exocytosis. These
cells express the substrates for all of the CNTs, but are resis-
tant to entry of BoNT/B, probably due to lack of functional
toxin receptors (Lomneth et al., 1991). PC12 cells express
syt I and IX and trace levels of syt IV (Zhang et al., 2002).
Because syts IX and IV do not bind BoNT/B and syt I binds
only in the presence of gangliosides (Fig. 1 A, middle), toxin
resistance could be due to the fact that these cells contain
low levels of gangliosides as compared with neurons (Walton
et al., 1988). We tested this idea by preloading exogenous
gangliosides into the plasma membrane of wild-type PC12
Figure 2. Mapping the BoNT/B-binding site within the luminal domain of syt II. (A) Binding assays were performed as in Fig. 1 A, using the 
indicated syt II truncation mutants. The top shows a schematic of the truncation mutants where ( ) denotes binding and ( ) denotes lack of 
binding. (B) Sequence of the amino terminus of syts I and II. The underlined region (residues 40–60 in syt II; residues 32–52 in syt I) is critical 
for binding BoNT/B; the asterisks indicate sequence differences. The transmembrane domain (TMD) is boxed. (C) Top; a peptide, P21, 
corresponding to residues 40–60 of syt II, plus a COOH-terminal cys residue was conjugated to agarose beads and used to pull-down toxin as 
described in A; a scrambled peptide, P21S, served as a negative control. Bottom; P21 (but not P21S) blocked the interaction between BoNT/B 
and the 1–87 fragment of syt II. Binding assays were performed as in A, but as a function of the indicated P21 or P21S concentration.T
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cells. As shown in Fig. 3 A, detectable toxin binding was ob-
served only when cells were loaded with gangliosides. Then,
we determined whether the toxin can enter ganglioside-
treated cells. To monitor entry, we assayed for cleavage of
the cytoplasmic substrate of BoNT/B, syb II (Schiavo et al.,
1992), by immunoblot analysis using anti-syb II antibodies.
Cleavage of syb II by BoNT/B occurred only when cells
were first preloaded with gangliosides (Fig. 3 B). These data
are consistent with a model in which syt I and gangliosides
cooperate to mediate the binding and entry of BoNT/B, and
are in agreement with biochemical data showing that the
toxin binds to syt I only in the presence of gangliosides. To
further test this model, we took advantage of a PC12 cell
line that lacks syt I (Syt I
 
 
 
; Shoji-Kasai et al., 1992). This
cell line is still capable of Ca
 
2
 
 
 
-triggered exocytosis, presum-
ably via the redundant action of syt IX (Fukuda et al., 2001;
Zhang et al., 2002). As shown in Fig. 3 C, BoNT/B failed to
cleave syb II in ganglioside-loaded syt I
 
 
 
 PC12 cells. These
data indicate that gangliosides plus syt I are both needed for
toxin entry.
We also assayed for entry of BoNT/A and E into PC12
cells. Entry was monitored by assaying for cleavage of their
substrate SNAP-25 (Blasi et al., 1993a; Schiavo et al.,
1993). BoNT/A cleaves SNAP-25 between residues 197–
198, thereby removing nine amino acids; BoNT/E cleaves
between residues 180–181 and removes 26 residues (Schi-
avo et al., 1993). Incubation of cells with nM concentra-
tions of BoNT/A and E resulted in similar degrees of cleav-
age of SNAP-25 in both wild-type (unpublished data) and
syt I
 
 
 
 cells (Fig. 3 D). Thus, both toxins are able to enter
syt I
 
 
 
 PC12 cells that have not been preloaded with gangli-
osides. These experiments demonstrate that syts I and II
are not required for entry of BoNT/A and E into PC12
cells, and that syt I
 
 
 
 cells are competent to take up at least
some CNTs.
 
Syt II is sufficient to mediate entry of BoNT/B 
into PC12 cells
 
To determine directly whether syt II can function as a recep-
tor for BoNT/B, we took advantage of the observation that
this syt isoform is able to bind BoNT/B to some extent in
the absence of gangliosides (Fig. 1 A). We generated PC12
cell lines that stably express syt II (Syt II
 
 
 
; Fig. 4 A), and ob-
served that they bind BoNT/B without preloading cells with
exogenous gangliosides (Fig. 4 B). A key finding was that ex-
pression of syt II was sufficient to reconstitute toxin entry
into the transfected cells, as shown by the cleavage of syb II
(Fig. 4 C). The efficiency of cleavage was proportional to the
level of syt II expression, and cleavage was not observed in
cells lacking syt II (Fig. 4 C, right). These findings demon-
strate that syt II can function as a receptor for BoNT/B
without preloading cells with exogenous gangliosides.
To further test whether binding and entry is mediated by
direct interactions between BoNT/B and the luminal do-
main of syt II, we determined whether fragments of syt II
that contain the BoNT/B-binding site inhibit toxin action.
As shown in Fig. 5 A, fragments corresponding to residues
1–267, 1–87, and 40–60 (P21) of syt II, blocked binding of
BoNT/B to syt II
 
 
 
 PC12 cells. Syt II fragment 61–267,
which lacks the luminal domain, and the scrambled peptide
P21S, failed to block binding of the toxin. We note that syt
II 1–267 and 61–267 contain an oligomerization domain
within residues 61–140, and also bind membranes via their
C2A domain, thus forming aggregates (Bai et al., 2000).
These aggregates are visualized in Fig. 5 A (bottom panels)
using an anti-His
 
6
 
 antibody that recognizes a His
 
6
 
 tag
present in these recombinant syt fragments. The syt 1–267
fragment also contains bound BoNT/B, as shown via the
anti-BoNT/B immunoreactivity in the syt II aggregates (Fig.
5 A, top). In contrast, cell-associated syt II 61–267 aggre-
gates did not contain BoNT/B (Fig. 5 A, bottom).
Figure 3. Entry of BoNT/B into PC12 cells is dependent on syt I expression and preloading of cells with gangliosides. (A) PC12 cells were 
either untreated or preloaded with gangliosides. Cells were then incubated with 50 nM BoNT/B for 48 h, fixed, permeabilized, and stained 
using a rabbit anti-BoNT/B antibody; the secondary antibody was goat anti–rabbit-FITC. Pre-loading cells with gangliosides resulted in toxin-
binding activity. (B) PC12 cells either were ( ) or were not ( ) preloaded with gangliosides; cells were then incubated with ( ) or without 
( ) 50 nM BoNT/B for 48 h and harvested. 20  g of each sample was subjected to SDS-PAGE and immunoblot analysis using anti-syb II 
(Cl 69.1) or anti-syt I (Cl 41.1) antibodies. Pre-loading cells with gangliosides mediated entry of toxin, as evidenced by cleavage of syb II. 
Syt I was probed to ensure equal loading on the gels. (C) Experiments were performed as in B above, except that wild-type PC12 cells were 
compared with the syt I
  cells.  / -SNAP was probed to ensure equal loading. In the absence of syt I, BoNT/B cannot enter PC12 cells to 
cleave syb II, even when cells have been preloaded with gangliosides. (D) Entry of BoNT/A and E into Syt I
  PC12 cells. Syt I
  PC12 cells 
were incubated with 30 nM BoNT/A or 50 nM BoNT/E for 48 h; entry was monitored by assaying for cleavage of SNAP-25. Asterisks denote 
SNAP-25 cleavage products.T
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More importantly, titration of syt II 1–267 resulted in the
dose-dependent protection of syb II cleavage; fragment 61–
267 had no protective effect (Fig. 5 B, top). Inclusion of
gangliosides increased the efficacy of protection by approxi-
mately threefold (Fig. 5 B, bottom), presumably by facilitat-
ing the already robust binding of syt II 1–267 to BoNT/B
(Fig. 1 A, bottom). This result is consistent with the obser-
vation that the binding partner with the highest affinity for
BoNT/B is composed of syt II plus gangliosides (Fig. 1 A,
bottom; Nishiki et al., 1996a). As a control, mixtures of gan-
gliosides and syt II fragment 61–267 were not able to pre-
vent cleavage of syb II (Fig. 5 B, bottom). P21 also yielded
dose-dependent protection, albeit at 
 
 
 
10-fold higher con-
centrations as compared with the 1–267 fragment (Fig. 5
C), presumably because it binds less tightly to BoNT/B than
the longer fragments of syt II. There is a concern that low
 
levels of detergent associated with the transmembrane do-
mains present in some of the syt fragments may affect the
uptake and action of the toxin. However, we did not observe
any apparent toxicity using these fragments. Also, the ability
of fragment 1–267 to block the action of the toxin cannot
be due to toxicity from associated detergent, as fragment
61–267 has the same transmembrane domain, yet fails to
provide any protection.
 
Activity-dependent entry of BoNT/B into vesicles 
that contain syt I
 
The data above suggest a model in which BoNT/B gains en-
try into PC12 cells by binding to the luminal domain of syt
I or syt II. This model predicts that BoNT/B will follow the
internalization of syts I and II from the cell surface and that
internalization will be activity dependent. To answer this
question, we first demonstrated that an anti-syt I luminal
domain antibody (
 
 
 
-syt I
 
N
 
) and BoNT/B can bind to syt I
simultaneously (Fig. S2 A, available at http://www.jcb.org/
cgi/content/full/jcb.200305098/DC1). This is the expected
result because the antibody recognizes the first 12 amino ac-
ids at the NH
 
2
 
 terminus of syt I, whereas the BoNT/B-bind-
ing site lies at the COOH-terminal end of the luminal do-
main.
We took advantage of this finding and determined
whether the antibody and toxin are taken up into the same
compartment in response to stimulation. PC12 cells were
preloaded with gangliosides and depolarized with high [K
 
 
 
]
to induce exocytosis of secretory vesicles in the presence of
 
 
 
-syt I
 
N
 
 antibodies and BoNT/B. Exocytosis and endocyto-
sis were allowed to proceed for 10 min, followed by exten-
sive washes to remove surface-bound antibody and toxin. As
shown in a confocal section (Fig. 6), both 
 
 
 
-syt I
 
N
 
 antibod-
ies and BoNT/B were internalized into the same compart-
ment. Depolarization of cells significantly increased the in-
ternalization of both the antibody and BoNT/B; only low
levels of internalization, due to spontaneous exocytosis and
recycling, were observed in the control (Fig. 6 A).
In contrast to the 
 
 
 
-syt I
 
N
 
 antibody, an antibody directed
against the cytoplasmic domain of syt I (
 
 
 
-syt I
 
C
 
) was not
taken-up (Fig. S2 B, available at http://www.jcb.org/cgi/
content/full/jcb.200305098/DC1), demonstrating that stain-
ing with the luminal domain antibody is not due to loss of
integrity of the cell membranes. Also, 
 
 
 
-syt I
 
N
 
 antibodies and
BoNT/B were not taken up into syt I
 
 
 
 PC12 cells (Fig. S2
B), further establishing that uptake requires the exposure of
the syt I luminal domain and is not due to bulk endocytosis.
These findings demonstrate that the luminal domain of syt I
is exposed on the surface of PC12 cells during exocytosis, and
that BoNT/B enters PC12 cells via organelles that contain syt
I. This latter observation was further confirmed by the colo-
calization of BoNT/B with an antibody directed against the
cytoplasmic domain (
 
 
 
-syt I
 
C
 
) of syt I (Fig. S2 C).
Similar results were obtained using syt II
 
 
 
 PC12 cells;
BoNT/B entered syt I containing vesicles in an activity-
dependent manner (unpublished data). We have been un-
able to localize syt II in the syt II
 
 
 
 cell lines using antibodies
currently available. However, syt II is colocalized with syt I on
secretory vesicles in brain, and is likely to be targeted to syt
I-containing organelles in PC12 cells (Osborne et al., 1999).
Figure 4. Syt II mediates entry of BoNT/B into PC12 cells. 
(A) Full-length mouse syt II was subcloned into pCDNA3.1( ) and 
used to transfect PC12 cells. Cells were selected with G418 and 
several independent monoclonal lines were established and screened 
for syt II expression by immunoblot analysis using a rabbit anti-syt II 
antibody; 30  g of protein from the syt II
  clones and 100  g from 
the syt II
  clones were loaded onto the gels. Clone no. 1, 5, and 10 
expressed syt II (syt II
 ), clone no. 8, 9, and 13 lacked syt II (syt II
 ). 
Because clone no. 5 expressed low levels of syt II (left), a 100- g 
sample from this clone was also included in the blots of the syt II
  
clones to confirm that this clone expresses syt II. (B) Wt or syt II
  
(clone no. 1) PC12 cells were decorated with 30 nM BoNT/B as 
described in Fig. 3 A. (C) Entry of 15 nM BoNT/B into PC12 cells 
was assayed as described in Fig. 3 B. Entry of the toxin was observed 
in all syt II
  clones, and was not observed in any of the syt II
  clones. 
As a control, a parental PC12 cell line was analyzed in parallel.T
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Activity-dependent uptake of BoNT/B 
into motor nerve terminals
 
The cause of death from BoNT/B intoxication is asphyxia-
tion due to blockade of neurotransmission at the diaphragm.
Therefore, we extended our analyses to explore the mecha-
nism of toxin entry into neurons in this tissue. As shown in
Fig. 7 A, stimulation with KCl results in a dramatic increase
in the levels of BoNT/B associated with the neuromuscular
junction (5.7-fold; Fig. 7 B), and a concomitant loss of syb
II immunoreactivity (3.2-fold; Fig. 7 C). The increase in
binding of BoNT/B and the loss of syb II were virtually
abolished by incubation with the syt II fragment 1–267/gan-
gliosides, but not by a mixture of syt II 61–267/gangliosides
(Fig. 7, A–C). These data demonstrate that uptake of
BoNT/B is activity dependent at its natural target. More-
over, binding and entry of the toxin can be completely pre-
vented by syt II fragments that contain the toxin-binding
site, whereas syt fragments lacking the toxin-binding site
have no effect.
 
Competitive inhibition of syt–BoNT/B interactions 
neutralizes BoNT/B in vivo
 
The experiments described above demonstrate that BoNT/
B enters PC12 cells and motor nerve terminals through in-
teractions with syts I and II plus gangliosides. To further
establish the physiological relevance of our findings, we de-
termined whether syt II fragments that contain the BoNT/
B-binding site can neutralize the effects of the toxin in
vivo. For these experiments, we used a rapid method to
evaluate toxicity in which the i.v. injection of large
amounts (10
 
5
 
–10
 
6
 
 LD
 
50
 
) of BoNT/B into mice results in
death on a time scale of minutes to hours, as opposed to
Figure 5. Syt II fragments that contain the BoNT/B-binding 
site block binding and entry of the toxin into syt II
  cells. 
(A) Cells were decorated with BoNT/B as in Fig. 3 A in the 
absence or presence of the indicated syt II fragments. Syt II 1–267 
and 61–267 were purified using a His6 tag at the amino 
terminus, and syt II 1–87 was purified as a GST fusion protein 
and eluted from beads using glutathione. Syt fragments 1–267 
and 1–87, as well as the P21 peptide (residues 40–60), 
blocked binding; 61–267 and P21S had no effect. The syt II 
1–267 and 61–267 fragments form aggregates bound to cell 
membranes as visualized with an anti-His6 antibody in the 
bottom; for syt II 1–267, these aggregates also contained 
BoNT/B. The final concentrations of recombinant protein and 
peptides in the media were 960 nM and 10  M, respectively; 
the final concentration of BoNT/B was 30 nM. (B) Syt II
  
PC12 cells (clone no. 1) were treated with 30 nM BoNT/B that 
was premixed with the indicated concentration of the syt II 
1–267 fragment in the absence (top) or presence (bottom) 
of 25  g/ml gangliosides for 48 h. Samples were analyzed by 
immunoblotting as described in Fig. 3 B. Cleavage of syb II was 
inhibited by the 1–267 fragment of syt II; inclusion of ganglio-
sides increased the ability of the syt fragment to block cleavage 
of syb II. Fragment 61–267 had no effect. (C) Experiments 
were performed as in A, but using the P21 or P21S peptides.T
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standard 4-d lethality assays (Boroff and Fleck, 1966;
Schantz and Kautter, 1978). This assay reduces the amount
of time that animals are exposed to the toxin. To this end,
we first established a standard curve to relate classically de-
termined LD
 
50
 
/ml values to the time-to-death values that
were determined using the rapid assay (Fig. 8 A). This plot
was then used to convert the experimentally measured
time-to-death to units of apparent LD
 
50
 
/ml. After this con-
version, the apparent LD
 
50
 
/ml values were used to calculate
the percentage of neutralization of the toxin by syt/gan-
glioside mixtures.
In contrast to the PC12 cell experiments, the range of
[syt II 1–267] that we tested in mice did not afford protec-
tion in the absence of gangliosides. This might be due to
the fact that the highest affinity receptor is composed of a
syt II–ganglioside complex, and that the highest affinity
scavenger is needed to compete with toxin binding in vivo.
Consistent with this model, syt II fragments 1–267 and
1–87, together with gangliosides, neutralized most of the
BoNT/B toxicity in mice (Fig. 8 B). It remains possible
that higher doses of syt II 1–267 could provide some de-
gree of protection in vivo.
Syt II 61–267 plus gangliosides did not neutralize the
toxin (Fig. 8 B), further establishing the essential role of
the luminal domain of syt II for toxin entry in vivo. The
potencies of syt II 1–267 and 1–87 were determined (Fig.
8 C); both fragments yielded dose-dependent protection at
sub-
 
 
 
M concentrations. Finally, prior i.v. injection with
syt II 1–267 or 1–87, mixed with gangliosides, neutralized
70–80% of BoNT/B that was injected 1 min later (Fig. 8
D), indicating that animals can be protected before expo-
sure to toxin. Together, these results support the idea that
the physiological receptor for BoNT/B is composed of syt
II and gangliosides.
 
Discussion
 
Botulism was first described almost 200 years ago (Kerner,
1817). Among the BoNTs, serotypes A, B, and E are the
most common causes of botulism in humans (Hatheway,
1995). To enter neurons, BoNTs first bind, with high affin-
ity and specificity, to presynaptic nerve terminals. Using bio-
chemical methods, a number of toxin-binding proteins have
been identified. At present, none of these binding partners
have been shown to be important for toxin entry; the identity
of the physiological receptors for the CNTs remains an open
question. Here, we demonstrate that syts I and II function as
receptors that mediate the entry of BoNT/B into cells.
First, we confirmed that BoNT/B binds to syts I and II. This
interaction is stoichiometric, highly specific, facilitated by gan-
gliosides, and is mediated by a region of syt that is transiently
exposed outside of cells during exocytosis. Using PC12 cells,
which are resistant to BoNT/B, we performed experiments to
reconstitute entry. These cells have low levels of gangliosides,
but express syt I. We found that BoNT/B is able to enter
PC12 cells if their plasma membranes are preloaded with suffi-
cient levels of gangliosides. Moreover, entry into ganglioside-
loaded cells was strictly dependent on the expression of syt I;
entry was abolished when syt I expression was disrupted. Next,
we took advantage of our observation that, in contrast to syt I,
syt II exhibits significant levels of toxin-binding activity in the
absence of gangliosides. Expression of syt II in PC12 cells re-
sulted in the binding and entry of the toxin into cells and over-
came the need for preloading the cells with gangliosides. In
summary, both loss-of-function (syt I
 
 
 
) and gain-of-function
experiments (syt II
 
 
 
) are consistent with a model in which
BoNT/B enters cells via interactions with syt I or syt II.
If syt mediates binding and entry of BoNT/B, then syt
ectodomains, which contain the toxin-binding site, should
block the action of the toxin. Using syt II
 
 
 
 PC12 cells, we
Figure 6. Activity-dependent internal-
ization of BoNT/B into syt I harboring 
organelles. (A) PC12 cells were preloaded 
with gangliosides and incubated with 50 
nM BoNT/B plus 10  l/ml  -syt IN anti-
bodies for 10 min at 37 C in either control 
or high [K
 ] buffers. Cells were then 
washed, fixed, and permeabilized as 
described in the Materials and methods 
section. Uptake of  -syt IN antibodies 
was assayed by staining with a rhodamine-
conjugated goat anti–mouse secondary 
antibody; internalized BoNT/B was 
stained using a rabbit anti-BoNT/B 
antibody and a FITC-conjugated goat 
anti–rabbit secondary antibody. Images 
were generated using a confocal micro-
scope; a single optical section from the 
middle of the cells is shown. Both  -syt 
IN and BoNT/B were internalized, into 
the same compartment(s), in an activity-
dependent manner. (B) An enlarged 
optical section of a single PC12 cell 
obtained as described in A. The merged 
images demonstrate a high degree of 
colocalization between internalized 
 -syt IN antibodies and BoNT/B.T
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1992; Juzans et al., 1996), providing a means of entry. It is
known that cholinergic neurons at the neuromuscular junc-
tion express syt II and are the major physiological targets of
BoNT/B (Dolly et al., 1984; Juzans et al., 1996). We ex-
plored this issue using motor neurons that innervate the dia-
phragm. Our data unambiguously demonstrate that binding
and uptake of BoNT/B is activity dependent and can be
blocked by syt fragments in conjunction with gangliosides at
the neuromuscular junction (Fig. 7). These results indicate
that the mechanism of toxin entry is similar between PC12
cells and motor neurons. Finally, these observations were ex-
tended to a whole animal study where we found that syt
fragment/ganglioside mixtures neutralized the toxin in mice.
Figure 7. Activity-dependent uptake of BoNT/B, followed by cleavage of syb II in rat diaphragm motor nerve terminals. (A) Rat diaphragm 
preparations were incubated with 5 nM BoNT/B in mammalian ringer. They were either unstimulated (control), stimulated with high 
potassium (stimulated), or stimulated in the presence of a mixture of BoNT/B and the protein fragment syt II 1–267 or 61–267 (1  M) plus 
gangliosides (25  g/ml). They were then fixed, permeabilized, and blocked. Control (unstimulated) nerve terminals show bright immuno-
fluorescence for syb II, and very dim labeling of BoNT/B. Stimulation during incubation with BoNT/B resulted in greatly reduced syb II 
immunofluorescence, whereas BoNT/B levels are markedly enhanced. Stimulation in the presence of both BoNT/B and syt II 1–267/gangliosides 
resulted in protection of nerve terminals, seen as both preservation of syb II staining, and greatly reduced levels of BoNT/B binding. (B) Quantification 
of BoNT/B levels under different conditions. Stimulation greatly enhances BoNT/B binding, and this can be blocked by coincubation with syt 
II 1–267/gangliosides. Syt fragment 61–267 plus gangliosides failed to block binding of BoNT/B. (C) Quantification of syb II levels. Syb II levels 
show a complementary pattern to those seen with BoNT/B. Levels of immunofluorescence are high in unstimulated tissue, but drop after 
stimulation. Inclusion of syt II 1–267/gangliosides but not 61–267/gangliosides with BoNT/B protects syb II from cleavage. In B and C, error 
bars represent the SEM (n   15–22).
observed that was indeed the case; fragments of syt II effec-
tively inhibited the binding of BoNT/B to the surface of
cells, and prevented the cleavage of syb II.
We studied the pathway of BoNT/B internalization into
PC12 cells using an antibody directed against the NH2 ter-
minus of syt I. We found that BoNT/B was co-internalized
with the antibody in an activity-dependent manner. These
results further support our conclusion that syts I and II are
functional receptors that mediate BoNT/B entry through re-
cycling of secretory vesicles. This is also likely to be the route
of entry of BoNT/B into neurons. In neurons, syts I and II
reside on synaptic vesicles where their luminal domains are
exposed during cycles of exo-endocytosis (Matteoli et al.,T
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Our model also indicates that syt I is a less effective recep-
tor, but at high local ganglioside concentrations, syt I may
also mediate entry of BoNT/B into neurons that lack syt II.
Therefore, the sensitivity of a particular neuron to BoNT/B
might depend on the local levels of gangliosides and whether
it expresses syt I or syt II.
All of our BoNT/B data are consistent with the double-
receptor model for CNTs, as proposed more than 15 years
ago (Montecucco, 1986). First, gangliosides facilitate syt–
BoNT/B interactions (Fig. 1 A; Nishiki et al., 1996a; Kozaki
et al., 1998); second, preloading cells with gangliosides is re-
quired for syt I-mediated toxin entry into wild-type PC12
cells (Fig. 3 B); third, preloading cells with gangliosides can
facilitate toxin entry that is mediated by syt II (unpublished
data); and fourth, gangliosides are required for syt ecto-
domains to protect mice from BoNT/B (Fig. 8 B). This hy-
pothesis is further supported by the finding that disruption
of ganglioside synthesis in mice reduces their sensitivity to
CNTs (Kitamura et al., 1999; Bullens et al., 2002).
The simplest explanation for the fact that syt II–ganglio-
side complexes efficiently block BoNT/B action in PC12
cells, intact hemi-diaphragm preparations, and mice is that
syt II plus gangliosides functions as the toxin receptor in
vivo. The in vivo experiments establish the physiological sig-
nificance of our analyses and provide a proof-of-principle
that receptor ectodomains might provide a novel means to
antagonize the action of bacterial toxins in animals.
Materials and methods
Cell lines, gangliosides, and toxins
A syt I deficit (Syt I
 ) PC12 cell line was provided by Y. Shoji-Kasai and M.
Takahashi (Mitsubishi Institute od Life Sciences, Machida, Japan; Shoji-
Kasai et al., 1992). A mixture of bovine brain gangliosides (18% GM1, 55%
GD1a, 10% GT1b, and 2% other gangliosides), hereafter designated as gan-
gliosides, were obtained from Calbiochem. BoNT/A, B, and E were puri-
fied as described previously (Dasgupta et al., 1970; Evans et al., 1986;
Schmidt and Siegel, 1986).
Antibodies
mAbs directed against syb II (69.1), syt I ( -syt IN, 604.4;  -syt IC, 41.1),
 / -SNAP (77.1), and SNAP-25 (71.2) were provided by R. Jahn and S. En-
gers (Max Planck Institute for Biophysical Chemistry, Gottingen, Ger-
many). Rabbit pAbs directed against syt II were provided by M. Fukuda
(RIKEN, Saitama, Japan; Fukuda and Mikoshiba, 2000).
Anti-BoNT/A, B, and E antibodies were generated by immunizing rab-
bits with formalin-treated purified neurotoxin; antibodies were affinity pu-
rified using immobilized neurotoxin.
cDNA and recombinant proteins
cDNA encoding rat syt I (Perin et al., 1990), mouse syt II and IX (Fukuda
and Mikoshiba, 2000), and rat syt IV (Vician et al., 1995) were provided by
T.C. Sudhof (University of Texas Southwestern Medical Center, Dallas,
TX), M. Fukuda, and H. Herschman (University of California, Los Angeles,
CA), respectively. Full-length syb II was generated as a GST fusion protein
as described previously (Lewis et al., 2001) using a cDNA provided by R.
Scheller (Stanford University, Stanford, CA).
To screen for toxin-binding activity, we generated truncated versions of
syt I, II, IV, and IX that lacked the C2B domain, but contained all other do-
mains. A number of additional constructs (truncations and chimeras, as in-
dicated in the figures) were also generated by PCR, subcloned into pGEX-
2T, and expressed and purified as described previously (Chapman et al.,
1996; Lewis et al., 2001). Syt II 1–267 and 61–267 were also subcloned
into pTrcHis and purified as NH2-terminal tagged His6 fusion proteins as
described previously (Chapman et al., 1996).
Pull-down assays
Recombinant proteins were immobilized as GST fusion proteins bound to
glutathione-Sepharose beads. Unless otherwise indicated, 10  g immobi-
lized protein was mixed with the indicated concentrations of BoNT/B, A,
or E either with ( ; 25  g/ml) or without ( ) gangliosides in 100  l TBS
(20 mM Tris and 150 mM NaCl, pH 7.4) plus 0.5% Triton X-100 for 1 h at
4 C. Beads were washed three times, bound proteins were solubilized by
boiling in SDS sample buffer and subjected to SDS-PAGE, and were visual-
ized by staining with Coomassie blue or by immunoblot analysis using
anti-toxin antibodies. In all blots, the immunoreactivity for the toxin heavy
chain is shown.
A peptide corresponding to residues 40–60 of mouse syt II, P21, and a
scrambled version of this peptide, P21S (IKMNDAEFFGKSNFQEKLEKEC),
were synthesized (Biotech Center, University of Wisconsin, Madison,
Madison, WI) with an added COOH-terminal cys that was used to conju-
gate them to agarose beads (at 1 mg/ml) using a Sulfolink Kit (Pierce Chem-
ical Co.). 50  l of the conjugated agarose gel was used in the pull-down
assays.
PC12 cell lines and immunoblot analysis
To generate cells that express syt II (syt II
 ), full-length mouse syt II was
subcloned into pCDNA3.1( ) (CLONTECH Laboratories, Inc.) and trans-
Figure 8. Protection of mice from BoNT/B toxicity using fragments 
of syt II. (A) Specific toxicity of BoNT/B in female mice was deter-
mined by an i.v. time-to-death assay. The standard curve was used 
to convert time-to-death (min) to LD50/ml. The resultant LD50/ml 
values were used to calculate percentage of neutralization of toxicity 
using the expression: 1  [LD50/ml(  syt II fragment)/ LD50/ml (  syt II 
fragment)]   100, where (  syt II fragment) refers to samples that 
contain toxin, gangliosides and recombinant proteins and (  syt II 
fragment) samples were composed of toxin and gangliosides only. 
(B) The indicated syt fragments (5  M) were premixed with ganglio-
sides (250  g/ml) and BoNT/B concentrations that lie in the linear 
range of the standard curve in A (i.e., 10
5–10
6 LD50/ml) for 10 min at 
RT, and injected i.v. (100  l) into mice. Percentage of neutralization 
was determined as described in A. In all the in vivo experiments, the 
indicated concentrations correspond to the initial concentration 
before i.v. injection; the dilution factor in the circulatory system is 
 1:10. (C) Experiments were performed as described in B, but as a 
function of the syt II 1–267 or 1–87 concentration. (D) Pre-injection 
of gangliosides (250  g/ml) plus syt II 1–267 (17  M) or 1–87 (20 
 M) mixtures protects mice from subsequent exposure to BoNT/B. 
Experiments were performed as in B, except that toxin was injected 
1 min after injection of the receptor complex. Note: in B–D, each 
data point represents the average of at least triplicate determinations; 
error was within   10%.T
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fected into PC12 cells via electroporation. Transfected cells were selected
with 1 mg/ml G418, and several independent monoclonal cell lines were
established. Cells were harvested in PBS plus 0.5% Triton X-100, 0.05%
SDS, and 5 mM PMSF, and were incubated for 30 min at 4 C on a shaker.
Samples were centrifuged at 21,000 g for 10 min, and the concentration of
protein in the supernatant was determined using bicinchoninic acid
(Pierce Chemical Co.). Samples were subjected to SDS-PAGE and immu-
noblot analysis; blots were developed using ECL (Pierce Chemical Co.).
Entry of BoNTs into PC12 cells
In experiments that did not involve preloading, cells were grown to 70%
confluence and incubated with BoNT for 48 h. For experiment in which
cells were preloaded with gangliosides, cells were grown to 80% conflu-
ence followed by incubation in serum-free media plus 250  g/ml ganglio-
sides. 24 h later, the serum-free/ganglioside media was replaced with com-
plete media, and the cells were incubated with toxin for 48 h. Cells were
harvested and entry of CNTs was assayed via immunoblot analysis using
antibodies directed against syb II or SNAP-25.
For blocking experiments, syt II 1–267 and syt II 61–267 were generated
as His6 fusion proteins; syt II 1–87 was generated as a GST fusion protein
that was eluted from beads using 10 mM glutathione plus 0.5% Triton
X-100. Protein fragments or peptides were premixed with BoNT/B in 200
 l TBS for 1 h at 4 C before adding into 2 ml cell culture media (per well
in a 6-well plate). In some cases, gangliosides were also added in the bind-
ing buffer (Fig. 5 B, bottom). The final concentration of BoNT/B was 30
nM, the final concentration of gangliosides was 25  g/ml, and the final [syt
fragment] is indicated in the figure legends.
Binding of BoNT/B to PC12 cells
Cells treated with toxin, plus or minus preincubation with syt fragments,
were washed three times with PBS, fixed with 4% PFA (15 min at RT), per-
meabilized with 0.1% Triton X-100 (for 10 min at RT), and stained with a
rabbit anti-BoNT/B primary antibody and an FITC-conjugated goat anti–rab-
bit secondary antibody (Jackson ImmunoResearch Laboratories). In the syt II
fragment competition assays described in Fig. 5, syt II 1–267 and 61–267
fragments form aggregates bound to cells (Bai et al., 2000); these were visual-
ized using a mouse anti-His6 primary antibody (QIAGEN) and a rhodamine-
conjugated goat anti–mouse secondary antibody (Jackson ImmunoResearch
Laboratories). The fluorescence images were obtained as described for the
motor nerve terminal experiments. We note that for these experiments, free
detergent was removed from the recombinant syt fragments by washing the
immobilized proteins with detergent-free buffers before elution. However, in
the case of syt II 1–87, low levels of Triton X-100 were needed to elute the
protein from the beads; because of this, experiments using this fragment were
performed within 6 h to avoid effects of detergent on the cells.
Antibody and toxin uptake experiments
Cells were treated with either control solution (15 mM Hepes, 145 mM
NaCl, 5.6 mM KCl, 2.2 mM CaCl2, 0.5 mM MgCl2, 5.6 mM glucose, 0.5
mM ascorbic acid, and 0.1% BSA, pH 7.4), or high [K
 ] solution (same as
control solution but adjusted to 95 mM NaCl and 56 mM KCl), for 10 min
at 37 C, in the presence of BoNT/B plus 10  l mAb against the luminal
( -syt IN; clone 604.4) or cytoplasmic domain of syt I ( -syt 1c; clone 41.1).
Cells were washed with culture media, incubated for 30 min at 37 C,
fixed, and permeabilized. A rabbit anti-BoNT/B primary antibody was used
to stain BoNT/B; staining was visualized using an FITC-conjugated goat
anti–rabbit secondary antibody. Rhodamine-conjugated goat anti–mouse
secondary antibodies were used to visualize internalized syt I antibodies.
Confocal images were collected with a confocal microscope (MRC 1000;
Bio-Rad Laboratories; Keck Center for Biological Imaging, University of
Wisconsin, Madison, Madison, WI) using a 100  oil immersion objective.
Co-immunoprecipitation
Recombinant syt I 1–265 GST was purified as described earlier in the Ma-
terials and methods section and was and cleaved from the GST tag using
thrombin. 5  l of mAb  -syt IN (604.4) was incubated with 300 nM BoNT/B,
with or without 1.5  M Syt I 1–265, in 100  l TBS plus 0.5% Triton X-100
and 25  g/ml gangliosides, for 1 h at 4 C. 30  l Protein G fast flow beads
(Amersham Biosciences) was added, samples were mixed for 1 h, beads
were washed three times in binding buffer, and bound material was ana-
lyzed by SDS-PAGE and immunoblotting using an anti-BoNT/B pAb and
 –syt IN (604.4).
Rat hemi-diaphragm experiments
Rat hemi-diaphragms were placed in an ice-cold ringer (in mM: NaCl
138.8, KCl 4, NaHCO3 12, KH2PO4 1, MgCl2 2, CaCl2 2, and glucose 11),
gassed with 95% CO2/5% O2. Stimulation was performed with a similar
solution where [KCl] was increased to 45 mM, and the NaCl appropriately
reduced. Hemi-diaphragms were incubated with high potassium ringer
containing 5 nM BoNT/B for 10 min at RT. In some experiments, the
BoNT/B was premixed with either the syt II fragment 1–267, or fragment
61–267, both mixed with 25  g/ml gangliosides. At the end of the stimula-
tion/incubation period, the preparations were fixed (4% PFA), permeabi-
lized (0.3% Triton X-100), and blocked in goat serum before immunola-
beling with a rabbit anti-BoNT/B antibody and a monoclonal anti-Syb II
antibody. Immunofluorescence was visualized using a FITC-conjugated
anti–rabbit antibody, and a TRITC-conjugated anti–mouse antibody. A re-
gion of muscle adjacent to the site of nerve entry (where a large number of
surface nerve terminals are to be found) was placed in a viewing chamber
with a glass bottom comprising a single coverslip. Immunofluorescence
images were obtained using a microscope (model TE300; Nikon), with a
cooled CCD camera (MicroMAX; Princeton Instruments) controlled by
MetaMorph
® software (Universal Imaging Corp.). Fluorescence intensities
were quantified using ImageJ software (National Institutes of Health, Be-
thesda, MD).
Neutralization of BoNT/B activity in vivo
For each batch of BoNT/B, the LD50 value for mice (20–22 g; Institute of
Cancer Research strain; ICR, Philadelphia, PA) was determined using stan-
dard methods (Schantz and Kautter, 1978). The LD50 corresponds to the
amount of toxin, introduced via i.p. injection, that results in 50% death af-
ter 4 d. Our preparations of BoNT/B had activities of  10
8 LD50/mg. For
toxin neutralization experiments, we made use of the more rapid i.v. time-
to-death assay (Boroff and Fleck, 1966). First, we generated a standard
curve in which the relationship between time-to-death of mice injected,
i.v., with 100  l BoNT/B (expressed in min) is plotted versus the specific
toxicity of BoNT/B that was determined using the standard method de-
scribed earlier in the Materials and methods section (log [LD50/ml]). Within
the linear range, 10
4–10
6 LD50/ml, this plot was used to convert experi-
mentally determined time-to-death, from i.v. injection of relatively large
doses of toxin, to LD50/ml values. For the toxin neutralization experiments,
BoNT/B was premixed with gangliosides alone (250  g/ml) or gangliosides
plus the indicated syt II fragments for 10 min at RT and then injected i.v.
into mice. In all experiments, the total injection volume was always 100
 l. Neutralization of the toxin is indicated by an extension in the time-to-
death of mice injected with toxin alone versus injection with toxin that had
been pre-mixed wit syt fragments/gangliosides. The increase in the time-to-
death was converted into a decrease in the apparent [LD50/ml] using the
standard curve, and the percentage of neutralization was calculated using
the expression: 1  [LD50/ml (  syt II fragment)/LD50/ml (  syt II fragment)]  
100, where (  syt II fragment) refers to samples that contain toxin, ganglio-
sides, and recombinant proteins, and (  syt II fragment) samples were
composed of toxin and gangliosides only.
Online supplemental material
Fig. S1 shows the mapping of the BoNT/B-binding site within the luminal
domain of syt I. Fig. S2 demonstrates the simultaneous and specific inter-
nalization of syt I luminal domain antibodies and BoNT/B into PC12 cells.
Online supplemental material available at http://www.jcb.org/cgi/content/
full/jcb.200305098/DC1.
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